Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCN-01 + GnP in Newly-Diagnosed Metastatic Pancreatic Cancer
NCT07701486Phase 2Recruiting
- Sponsor
- Theriva Biologics
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of zabilugene almadenorepvec in pancreatic ductal adenocarcinoma (PDAC), sponsored by Theriva Biologics. Started Jul 2026; status: recruiting.
02
Drugs
zabilugene almadenorepvec
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07701486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07701486.